Physician profile
William E Smeal
NPI 1497710701
$6,856.94
in general payments reported to CMS, 2019-2025
35 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $253 · 2021: $284 · 2022: $869 · 2023: $1,267 · 2024: $1,750 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,261.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $835.48 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $785.89 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $621.70 | 2019-2025 | Lifevest |
| Amgen INC. | $607.14 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $585.94 | 2019-2024 | Xarelto |
| Pfizer INC. | $546.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $398.75 | 2019-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $375.98 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.07 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $263.40 | 2023-2025 | Watchman Flx, S-Icd System Magnet, General - Tachy |
| Sanofi-Aventis U.S. LLC | $180.01 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $154.39 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $141.40 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Amarin Pharma, INC. | $124.61 | 2019-2022 | |
| Abiomed | $100.01 | 2024-2025 | Impella |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Smeal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.